326 research outputs found
Recommended from our members
Genetic Predisposition to Dyslipidemia and Type 2 Diabetes Risk in Two Prospective Cohorts
Dyslipidemia has been associated with type 2 diabetes, but it remains unclear whether dyslipidemia plays a causal role in type 2 diabetes. We aimed to examine the association between the genetic predisposition to dyslipdemia and type 2 diabetes risk. The current study included 2,447 patients with type 2 diabetes and 3,052 control participants of European ancestry from the Nurses’ Health Study and the Health Professionals Follow-up Study. Genetic predisposition to dyslipidemia was estimated by three genotype scores of lipids (LDL cholesterol, HDL cholesterol, and triglycerides) on the basis of the established loci for blood lipids. Linear relation analysis indicated that the HDL cholesterol and triglyceride genotype scores, but not the LDL cholesterol genotype score, were linearly related to elevated type 2 diabetes risk. Each point of the HDL cholesterol and triglyceride genotype scores was associated with a 3% (odds ratio [OR] 1.03 [95% CI 1.01–1.04]) and a 2% (1.02 [1.00–1.04]) increased risk of developing type 2 diabetes, respectively. The ORs were 1.39 (1.17–1.65) and 1.19 (1.01–1.41) for type 2 diabetes by comparing extreme quartiles of the HDL cholesterol genotype score and triglyceride genotype score, respectively. In conclusion, genetic predisposition to low HDL cholesterol or high triglycerides is related to elevated type 2 diabetes risk
ADAR1 restricts LINE-1 retrotransposition
Abstract
Adenosine deaminases acting on RNA (ADARs) are involved in RNA editing that converts adenosines to inosines in double-stranded RNAs. ADAR1 was demonstrated to be functional on different viruses exerting either antiviral or proviral effects. Concerning HIV-1, several studies showed that ADAR1 favors viral replication. The aim of this study was to investigate the composition of the ADAR1 ribonucleoprotein complex during HIV-1 expression. By using a dual-tag affinity purification procedure in cells expressing HIV-1 followed by mass spectrometry analysis, we identified 14 non-ribosomal ADAR1-interacting proteins, most of which are novel. A significant fraction of these proteins were previously demonstrated to be associated to the Long INterspersed Element 1 (LINE1 or L1) ribonucleoparticles and to regulate the life cycle of L1 retrotransposons that continuously re-enter host-genome.Hence, we investigated the function of ADAR1 in the regulation of L1 activity.By using different cell-culture based retrotransposition assays in HeLa cells, we demonstrated a novel function of ADAR1 as suppressor of L1 retrotransposition. Apparently, this inhibitory mechanism does not occur through ADAR1 editing activity. Furthermore, we showed that ADAR1 binds the basal L1 RNP complex. Overall, these data support the role of ADAR1 as regulator of L1 life cycle
Molecular cloning of the human rad gene: gene structure and complete nucleotide sequence
AbstractWe have isolated and sequenced human genomic DNA clones encoding the Ras-related GTP-binding protein, Rad. The gene spans 3.75 kb and consists of five exons and four introns. Translation initiates from the first of two in-frame methionine residues in the second exon. Several potential transcription cis-elements were revealed throughout the 1.7 kb 5′-flanking region, including ‘E box’ and CArG binding sites for regulators of transcription in muscle
Diabetes mellitus correlates with increased biological age as indicated by clinical biomarkers
Chronological age (CA) is determined by time of birth, whereas biological age (BA) is based on changes on a cellular level and strongly correlates with morbidity, mortality, and longevity. Type 2 diabetes (T2D) associates with increased morbidity and mortality; thus, we hypothesized that BA would be increased and calculated it from biomarkers collected at routine clinical visits. Deidentified data was obtained from three cohorts of patients (20-80 years old)-T2D, type 1 diabetes (T1D), and prediabetes-and compared to gender- and age-matched non-diabetics. Eight clinical biomarkers that correlated with CA in people without diabetes were used to calculate BA using the Klemera and Doubal method 1 (KDM1) and multiple linear regression (MLR). The phenotypic age (PhAge) formula was used with its predetermined biomarkers. BA of people with T2D was, on average, 12.02 years higher than people without diabetes (p \u3c 0.0001), while BA in T1D was 16.32 years higher (p \u3c 0.0001). Results were corroborated using MLR and PhAge. The biomarkers with the strongest correlation to increased BA in T2D using KDM were A1c (R2 = 0.23, p \u3c 0.0001) and systolic blood pressure (R2 = 0.21, p \u3c 0.0001). BMI had a positive correlation to BA in non-diabetes subjects but disappeared in those with diabetes. Mortality data using the ACCORD trial was used to validate our results and showed a significant correlation between higher BA and decreased survival. In conclusion, BA is increased in people with diabetes, irrespective of pathophysiology, and to a lesser extent in prediabetes
MEOX2 Regulates the Growth and Survival of Glioblastoma Stem Cells by Modulating Genes of the Glycolytic Pathway and Response to Hypoxia
The most widely accepted hypothesis for the development of glioblastoma suggests that
glioblastoma stem-like cells (GSCs) are crucially involved in tumor initiation and recurrence as
well as in the occurrence of chemo- and radio-resistance. Mesenchyme homeobox 2 (MEOX2) is a
transcription factor overexpressed in glioblastoma, whose expression is negatively correlated with
patient survival. Starting from our observation that MEOX2 expression is strongly enhanced in six
GSC lines, we performed shRNA-mediated knock-down experiments in two different GSC lines and
found that MEOX2 depletion resulted in the inhibition of cell growth and sphere-forming ability
and an increase in apoptotic cell death. By a deep transcriptome analysis, we identified a core group
of genes modulated in response to MEOX2 knock-down. Among these genes, the repressed ones
are largely enriched in genes involved in the hypoxic response and glycolytic pathway, two strictly
related pathways that contribute to the resistance of high-grade gliomas to therapies. An in silico
study of the regulatory regions of genes differentially expressed by MEOX2 knock-down revealed
that they mainly consisted of GC-rich regions enriched for Sp1 and Klf4 binding motifs, two main
regulators of metabolism in glioblastoma. Our results show, for the first time, the involvement of
MEOX2 in the regulation of genes of GSC metabolism, which is essential for the survival and growth
of these cells
Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria
OBJECTIVE
Progressive decrease in the glomerular filtration rate (GFR), or renal decline, in
type 1 diabetes (T1D) is observed in patients with macroalbuminuria. However,
it is unknown whether this decline begins during microalbuminuria (MA) or
normoalbuminuria (NA).
RESEARCH DESIGN AND METHODS
The study group (second Joslin Kidney Study) comprises patients with T1D and NA
(n = 286) or MA (n = 248) who were followed for 4-10 years (median 8 years). Serial
measurements (median 6, range 3–16) of serum creatinine and cystatin C were
used jointly to estimate GFR (eGFRcr-cys) and assess its trajectories during
follow-up.
RESULTS
Renal decline (progressive eGFRcr-cys loss of at least 3.3% per year) occurred in
10% of the NA and 35% of the MA (P , 0.001). In both groups, the strongest
determinants of renal decline were baseline serum concentrations of uric acid
(P , 0.001) and tumor necrosis factor receptor 1 or 2 (TNFR-1 or -2, P , 0.001).
Other significant risk factors included baseline HbA1c, age/diabetes duration, and
systolic blood pressure. Relative impacts of these determinants were similar in NA
and MA. Renal decline was not associated with sex or baseline serum concentration of TNF-a, IL-6, IL-8, IP-10, MCP-1, VCAM, ICAM, Fas, or FasL.
CONCLUSIONS
Renal decline in T1D begins during NA and it is determined by multiple factors,
similar to MA. Thus, this early decline is the primary disease process leading to
impaired renal function in T1D. Changes in albumin excretion rate, such as the
onset of MA or its progression to macroalbuminuria, are either caused by or develop in parallel to the early renal declin
Association of the 1q25 diabetes-specific coronary heart disease locus with slterations of the γ-glutamyl cycle and increased methylglyoxal levels in endothelial cells
A chromosome 1q25 variant (rs10911021) has been associated with coronary heart disease (CHD) in type 2 diabetes. In human umbilical vein endothelial cells (HUVECs), the risk allele "C" is associated with lower expression of the adjacent gene GLUL encoding glutamine synthase, converting glutamic acid to glutamine. To further investigate the mechanisms through which this locus affects CHD risk, we measured 35 intracellular metabolites involved in glutamic acid metabolism and the γ-glutamyl cycle in 62 HUVEC strains carrying different rs10911021 genotypes. Eight metabolites were positively associated with the risk allele (17-58% increase/allele copy, P = 0.046-0.002), including five γ-glutamyl amino acids, β-citryl-glutamate, N-acetyl-aspartyl-glutamate, and ophthalmate-a marker of γ-glutamyl cycle malfunction. Consistent with these findings, the risk allele was also associated with decreased glutathione-to-glutamate ratio (-9%, P = 0.012), decreased S-lactoylglutathione (-41%, P = 0.019), and reduced detoxification of the atherogenic compound methylglyoxal (+54%, P = 0.008). GLUL downregulation by shRNA caused a 40% increase in the methylglyoxal level, which was completely prevented by glutamine supplementation. In summary, we have identified intracellular metabolic traits associated with the 1q25 risk allele in HUVECs, including impairments of the γ-glutamyl cycle and methylglyoxal detoxification. Glutamine supplementation abolishes the latter abnormality, suggesting that such treatment may prevent CHD in 1q25 risk allele carriers
- …